|
1004 来自SCI天天读 00:00 01:58 SCI 4 October 2019 HER2-targeted therapies — a role beyond breast cancer
Abstract HER2 is an established therapeutic target in a large subset of women with breast cancer; a variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1) have been approved for the treatment of HER2-positive breast cancer. HER2是一个已确定的靶标，在很大一部分乳腺癌患者中受用;包含曲妥珠单抗、培妥珠单抗、拉帕替尼、纳拉替尼和曲妥珠单抗(T-DM1)在内的多种药物已被批准用于治疗HER2阳性乳腺癌。 HER2 is also overexpressed in subsets of patients with other solid tumours. Notably, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric cancer, and has become the standard-of-care treatment for this group of patients. However, trials involving pertuzumab, lapatinib and T-DM1 have failed to provide significant improvements in the outcomes of patients with HER2-positive gastric cancer. HER2-targeted therapies are also being tested in patients with other solid tumours harbouring HER2 overexpression, and/or amplifications or other mutations of the gene encoding HER2 (ERBB2), including biliary tract, colorectal, non-small-cell lung and bladder cancers. 而HER2在其他实体肿瘤患者的亚群中也过表达。值得注意的是，一线化疗中加入曲妥珠单抗提高了HER2阳性胃癌患者的总体生存，并已成为此类患者的标准治疗。HER2靶向疗法也正在其他有HER2过表达，和/或HER2编码基因(ERBB2)的扩增或其他突变的实体肿瘤（包括胆道、结肠直肠癌、非小细胞肺癌和膀胱癌）患者中进行测试。 The experience with gastric cancer suggests that the successes observed in HER2-positive breast cancer might not be replicated in these other tumour types, owing to differences in the level of HER2 overexpression and other aspects of disease biology. In this Review, we describe the current role of HER2-targeted therapies beyond breast cancer and also highlight the potential of novel HER2-targeted agents that are currently in clinical development. 胃癌的经验表明，由于HER2过表达水平和疾病生物学其他方面的差异，在HER2阳性乳腺癌中观察到的成功可能不会在其他类型的肿瘤中复制。在这篇综述中，我们描述了目前HER2靶向治疗在乳腺癌之外的作用，并强调了目前正在临床开发的新型HER2靶向药物的潜力。 喜欢SCI天天读的理由 陪您一起学习SCI医学论文 每天5分钟，让自己的英语牛逼起来 特殊福利让您惊喜连连 |
|
|
